SUPERNUS PHARMACEUTICALS INC
For the period ended Sep 30, 2024. Filed Nov 4, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 4, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
(a)None.
(b)None.
(c)Insider Trading Arrangements and Policies.
| Name and Title of Director or Officer | Rule 10b5-1 Trading Arrangement(1) | Trading Arrangement Adopted or Terminated | Date of Adoption or Termination | Duration of Trading Arrangement | Aggregate Number of Securities to be Purchased Pursuant to Trading Arrangement | Aggregate Number of Securities to be Sold Pursuant to Trading Arrangement |
|---|---|---|---|---|---|---|
| Jack Khattar, President, Chief Executive Officer and Director | Yes | Terminated | August 12, 2024 | First Transaction Date through August 12, 2024 | — | 75,037 |
| Padmanabh BhattSVP, Chief Scientific Officer, Intellectual Property | Yes | Adopted | September 3, 2024 | First Transaction Date through March 31, 2025 | 131,995 | 131,995 (2) |
(1) Indicates whether the trading arrangement is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
(2)This trading arrangement covers the exercise and sale of stock options, with a portion of such sales limited to an amount reasonably estimated such that the net proceeds from the sale are sufficient to cover the exercise cost and taxes associated with the exercise of the stock options.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.